US-based Tanvex BioPharma has submitted its Biologics License Application (BLA) for TX05, a proposed biosimilar to the reference product Herceptin. TX05 is indicated for breast cancer and gastric cancer. The review of BLA would be a 10-month to 12-month time frame.   

According to IQVIA data 2020, the Herceptin sales in US market hit $2.3 billion. There are different treatment options for breast cancer, including biologics such as Herceptin, Avastin, Perjeta and Kadcyla.

News compiled by IBMI; Source in Chinese: news.cnyes.com